Our company provides Steboronine® for the investigator-initiated specified clinical trial regarding Boron Neutron Capture Therapy (BNCT) (research code: jRCTs03122037) targeting recurrent breast cancer at Edogawa Hospital in Tokyo. Now, the paper, titled “The Effects of Boron Neutron Capture Therapy on the Lungs in Recurrent Breast Cancer Treatment”, has been published in Cureus online journal.
This is the world’s first accelerator based BNCT clinical trial with patients, whose breast cancer had recurred after prior radiotherapy. The paper generally introduces observations on the lungs in the first three cases.
The study aimed to evaluate the safety and efficacy of BNCT with the object of further applying the therapy to the thoracic region. The study focuses on the dose response of this region after BNCT, especially concerning radiation pneumonitis. The preliminary findings of the first three cases of this study showed no radiation pneumonitis within 3 months after BNCT, nor adverse event of grade 3 or higher within the observation period of 90 days after BNCT.
Although the observation period is not long enough for precise evaluation, this study is deemed to help establishing BNCT as new possibility for breast cancer treatment and enlarge the scope of BNCT application in the thoracic region.
The article can be found following this link: [https://www.cureus.com/articles/239953-the-effects-of-boron-neutron-capture-therapy-on-the-lungs-in-recurrent-breast-cancer-treatment#!/ ]
In addition, we believe this paper will serve as reference for the basket-type clinical trial for thoracic malignant cancers that our company is planning.